Applied Genomics

Eyeing a commercial launch for Mammostrat in the fourth quarter of this year, Clarient highlighted publication of data further validating the test as “an aid for risk stratifying early stage hormone receptor-treated breast cancer patients."

Clarient Insight Dx Pulmotype is a five-antibody immunohistochemistry test that the company said can be used to aid in the histological distinction between adenocarcinoma and squamous cell carcinoma in NSCLC tumor specimens.

Clarient plans to commercialize Applied Genomics' five-antibody immunohistochemistry test for non-small cell lung cancer, called Pulmotype, within its network of pathologists by the first quarter of 2010.

Applied Genomics is gearing up to launch a lung cancer diagnostic panel intended to help physicians make treatment decisions.

People In the News

Lai Named SVP of R&D at Gen-Probe, Jorge Leon Joins ParagonDx SAB, Strategic Diagnostics Hires Two Execs, and More.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.